MRVI at a glance
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI, SEC CIK 1823239) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.7 million (down 28.3% from FY2024) and a net loss of $130.8 million. Diluted EPS was -$0.90.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) shares worth $299.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by ORESHACK KURT on June 10, 2026 of 25,000 shares at $5.10 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $185.7M
- −28.3% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 29 funds
- $299.7M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $51.4M, up from $47.4M YoY
- TriLink revenue $34.7M vs $31.1M, strongest segment
- Cygnus revenue $16.8M vs $16.3M, weakest segment growth
- SG&A $32.1M vs $38.7M; R&D $3.7M vs $4.9M
- No second-quarter CleanCap revenue; no further high-volume orders expected in 2026
Risk Factors
- No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
- No newly added risk factor identified for the quarter
- Regulatory and compliance risks remain those carried forward from the 2025 Form 10-K
- No director or officer adopted or terminated Rule 10b5-1 arrangements during three months ended June 30, 2026
AI summary of the MRVI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced by Maravai LifeSciences
- Full results and management commentary furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $51.4M, up 8.5% year over year, led by TriLink growth of 11.5%
- Adjusted EBITDA $8.7M versus $(10.4)M, signaling substantial operating leverage despite $21.6M net loss
Item 1.01: Entry into a Material Definitive Agreement
- $150M term loan plus $30M revolver, both maturing June 2, 2032
- Refinancing funded with $98.5M cash, replacing and terminating the 2020 credit agreement
Item 7.01: Regulation FD Disclosure
- No substantive Regulation FD disclosure provided in the excerpt
- Text is a securities-law disclaimer, not operating or financial information
Item 1.02: Termination of a Material Definitive Agreement
- Prior Credit Agreement terminated on June 2, 2026
- All outstanding borrowings and accrued interest prepaid in full
Item 5.07: Submission of Matters to a Vote of Security Holders
- Shareholders elected Bernd Brust, Gregory T. Lucier, and Luke Marker to three-year director terms ending at the 2029 annual meeting
- 236,082,968 shares represented, establishing a quorum against 258,180,170 shares outstanding
AI summaries of MRVI 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MRVI
Don't miss the next MRVI filing
- Alerts as it files. A push when MRVI files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MRVI, by share count.
- Ask anything. An AI agent that reads every MRVI filing and answers with sources.
MRVI alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Asarpota Rajesh | F | Sep 30, 2026 | 5,465 | $7.65 |
| Brust Bernd | F | Sep 8, 2026 | 29,250 | $7.32 |
| Asarpota Rajesh | F | Aug 31, 2026 | 5,465 | $7.68 |
| Brust Bernd | F | Aug 10, 2026 | 29,250 | $6.23 |
| Asarpota Rajesh | F | Jul 30, 2026 | 5,465 | $6.59 |
| Brust Bernd | F | Jul 8, 2026 | 29,250 | $5.92 |
| Asarpota Rajesh | F | Jun 30, 2026 | 65,584 | $6.39 |
| ORESHACK KURT | Sell | Jun 10, 2026 | 25,000 | $5.10 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $259.2M | $185.7M |
| Gross Profit | - | $108.3M | $34.0M |
| Operating Income | - | -$235.6M | -$215.3M |
| Net Income | - | -$144.8M | -$130.8M |
| Gross Margin | - | 41.8% | 18.3% |
| Op. Margin | - | -90.9% | -115.9% |
| Net Margin | - | -55.9% | -70.4% |
| Balance Sheet | |||
| Total Assets | - | $1.0B | $770.6M |
| Equity | - | $325.3M | $212.4M |
| ROE | - | -44.5% | -61.6% |
| Per Share | |||
| EPS | $-0.90 | $-1.05 | $-0.90 |
| Cash Flow | |||
| Operating CF | - | $7.5M | -$57.6M |
| CapEx | $65.6M | $29.7M | $13.1M |
Source: XBRL data in MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MRVI share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $299.7M |
| Q1 2026 | 28 | $106.4M |
| Q4 2025 | 24 | $118.8M |
| Q3 2025 | 25 | $103.6M |
| Q2 2025 | 27 | $94.8M |
| Q1 2025 | 22 | $74.9M |
| Q4 2024 | 18 | $164.3M |
| Q3 2024 | 19 | $161.2M |
- Millennium Management+4.86M (+295%)
- JPMorgan Chase & Co+2.24M (+626%)
- Prudential Financial+2.13M (+11552%)
- Two Sigma Investments+676.0K (+43%)
- Citadel Advisors LLC+638.3K (+43%)
- Morgan Stanley−1.41M (-43%)
- Goldman Sachs Group−379.0K (-19%)
- Citigroup−170.8K (-35%)
- Vanguard Capital Management LLC−166.0K (-3%)
- Northern Trust−110.6K (-10%)
- Hilltop Holdings Inc.+75.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 192 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MRVI filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| SC 13G | Sep 29, 2026 | - | - | |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 7, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jul 10, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| SC 13G | Jun 29, 2026 | - | - | |
| SC 13G | Jun 23, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | May 29, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
MRVI SEC filings: frequently asked questions
Which institutions hold MRVI stock?
As of June 30, 2026, the largest MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) holders among the 13F filers tracked by SignalX were BlackRock ($62.2 million), Millennium Management ($40.6 million), Vanguard Capital Management LLC ($33.0 million), Renaissance Technologies LLC ($28.7 million), State Street Corp ($18.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MRVI's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.7 million (down 28.3% from FY2024) and a net loss of $130.8 million. Diluted EPS was -$0.90. The figures come from the XBRL data in the 10-K.
What did MRVI report in its latest 8-K?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced by Maravai LifeSciences.
What are the latest MRVI SEC filings?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 7, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on October 1, 2026.
What is MRVI's SEC CIK number?
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)'s SEC Central Index Key (CIK) is 1823239. EDGAR lists every MRVI filing under that number.
Ask anything about MRVI
The research agent reads MRVI's filings, financials, insider trades and 13F holders, then answers with sources.